4-(3-methoxyphenoxy)-benzene-1,2-diamine | 43156-27-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-methoxyphenoxy)-benzene-1,2-diamine
• 英文别名: 4-(3-Methoxyphenoxy)benzene-1,2-diamine
• CAS: 43156-27-0
• 化学式: C₁₃H₁₄N₂O₂
• 分子量: 230.266
• InChiKey: CISRMAKNMWVKBI-UHFFFAOYSA-N

物化性质

• 沸点：
  400.6±35.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  70.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(3-methoxyphenoxy)-benzene-1,2-diamine 在 sodium hydride 、 三乙胺 作用下， 以 氯仿 、 邻二甲苯 为溶剂， 反应 32.0h， 生成 5-methylthio-1-(p-bromophenyl)-3a-(p-methoxyphenyl)-9-(m-methoxyphenoxy)-3a,4-dihydro-<1,2,4>-oxadiazolo<4,5-a><1,5>benzodiazepine
  参考文献：
  名称：

  5-甲硫基-4 H -1-（对位取代苯基）-3a-（对位取代苯基）-9-[（m- ;和对位取代）-苯氧基] -3a的合成及光谱性质4-二氢[1,2,4]恶二唑[4,5- a ] [1,5]苯并二氮杂s

  摘要：

  具有潜在的有用药理特性的八种新型取代的[1,2,4]恶二唑并[4,5- a ] [1,5]苯并二氮杂s的制备；描述了通过由苯并氧杂氨酰氯和三乙胺原位产生的苯甲腈氧化物的1，3-环加成反应到1，5-苯并二氮杂卓衍生物。ir，1 H-nmr，13 C-nmr和ms证实了所有产物的结构。

  DOI：

  10.1002/jhet.5570360224
• 作为产物：
  描述：

  4-(-3-methoxyphenoxy)-2-nitroaniline 在 tin(II) chloride dihdyrate 作用下， 以 乙醇 、 水 为溶剂， 反应 12.0h， 以71%的产率得到4-(3-methoxyphenoxy)-benzene-1,2-diamine
  参考文献：
  名称：

  Discovery of Picomolar ABL Kinase Inhibitors Equipotent for Wild Type and T315I Mutant via Structure-Based de Novo Design

  摘要：

  Although the constitutively activated break-point cluster region-Abelson (ABL) tyrosine kinase is known to cause chronic myelogenous leukemia (CML), the prevalence of drug-resistant ABL mutants has made it difficult to develop effective anti-CML drugs. With the aim to identify new lead compounds for anti-CML drugs, we carried out a structure-based de novo design using the scoring function improved by implementing an accurate solvation free energy term. This approach led to the identification of ABL inhibitors equipotent for the wild type and the most drug-resistant T315I mutant of ABL at the picomolar level. Decomposition analysis of the binding free energy showed that a decrease in the desolvation cost for binding in the ATP-binding site could be as important as the strengthening of enzyme-inhibitor interaction to enhance the potency of an ABL inhibitor with structural modifications. A similar energetic feature was also observed in free energy perturbation (FEP) calculations. Consistent with the previous experimental and computational studies, the hydrogen bond interactions with the backbone groups of Met318 proved to be the most significant binding forces to stabilize the inhibitors in the ATP-binding sites of the wild type and T315I mutant. The results of molecular dynamics simulations indicated that the dynamic stabilities of the hydrogen bonds between the inhibitors and Met318 should also be considered in designing the potent common inhibitors of the wild-type and T315I mutant of ABL.

  DOI：

  10.1021/ja311756u

文献信息

• Synthesis and spectral properties of methyl 5-[(<i>o</i>-,<i>m</i>-, and<i>p</i>-R)-phenoxy]-2-benzimidazolecarbamate
  作者：Eduardo Cortés Cortés、Luis Angel Araluce Anaya

  DOI：10.1002/jhet.5570340307

  日期：1997.5

  The preparation of eleven novel methyl 5-[(o-, m-, p-R)-phenoxy-2-benzimidazolecarbamates with possible pharmacological activity as anthelmintics is described. The structure of all products was corroborated by ir, 1H-nmr, 13C-nmr and mass spectra.

  描述了十一种新颖的5-[（o-，m-，p -R）-苯氧基-2-苯并咪唑氨基甲酸酯甲酯，其具有可能的药理活性作为驱虫药。ir，1 H-nmr，13 C-nmr和质谱证实了所有产物的结构。
• 인돌 유도체 화합물, 이를 포함하는 Ａｂｌ 키나제 저해제 조성물 및 이상세포 성장 질환의 예방 및 치료용 약학 조성물
  申请人：Korea Advanced Institute of Science and Technology 한국과학기술원(319980988661) BRN ▼314-82-01980

  公开号：KR101546743B1

  公开（公告）日：2015-08-24

  본 발명은 하기 [화학식 1]로 표시되는 벤즈이미다졸, 벤조싸이아졸 및 이미다조 피리딘 유도체 화합물, 이를 포함하는 Abl 키나제 저해제 조성물 및 이상세포 성장 질환의 예방 및 치료용 약학 조성물에 관한 것으로서, 본 발명에 따른 벤즈이미다졸, 벤조싸이아졸 또는 이미다조피디린 유도체 화합물 및 이의 약학적 수용 가능한 염은 Abl 키나제에 대한 저해제로서 비정상적 세포 성장, 기능 또는 거동으로부터 야기되는 질환, 특히, 암, 면역 질환, 심혈관 질환, 바이러스 감염 질환, 염증성 질환, 내분비 질환 및 신경성 질환을 치료하는데 사용할 수 있다. [화학식 1]

  本发明涉及苯并咪唑、苯并噻唑和咪唑吡啶衍生物化合物，其用化学式1表示，以及包含这些化合物的Abl激酶抑制剂组合物和用于预防和治疗异常细胞增长疾病的药学组合物。根据本发明，苯并咪唑、苯并噻唑或咪唑吡啶衍生物化合物及其药学上可接受的盐可作为针对Abl激酶的抑制剂，可用于治疗由异常细胞增长、功能或行为引起的疾病，特别是癌症、免疫性疾病、心血管疾病、病毒感染性疾病、炎症性疾病、内分泌疾病和神经性疾病。【化学式1】
• Synthesis and spectral properties of 2-methylthio-3<i>H</i>-7-[(<i>o</i>-;<i>m</i>- and<i>p</i>-substituted)phenoxy]-4-(<i>p</i>-substituted-phenyl)-[1,5]benzodiazepines
  作者：Eduardo Cortés Cortés、Cristina A. Cortés Romero、Olivia García Mellado

  DOI：10.1002/jhet.5570390633

  日期：2002.11

  A series of eleven new 2-methylthio-3H-7-[(o-; m- and p-substituted) phenoxy]-4-(p-substituted-phenyl)-[1,5]benzodiazepines, which have potentially useful pharmacological activities, has been synthesized by condensing the 4-[(o-; m- and p-R1)phenoxy]-1,2-phenylendiamines with 3,3-dimercapto-1-(p-R2-phenyl)-2-propen-1-one. Afterward the lH-[1,5]benzodiazepine-2-thiones obtained were treated with sodium

  一系列十一种新的2-甲硫基-3 H -7-[（o- ; m-和对-取代的）苯氧基] -4-（对-取代的苯基）-[1,5]苯并二氮杂通过缩合4-[（o- ; m-和p -R 1）苯氧基] -1,2-苯基苯二胺与3,3-二巯基-1-（p -R 2-苯基）-合成药理活性2-prop-1-1。然后，将得到的1 H- [1，5]苯并二氮杂-2-硫酮用氢化钠和甲基碘处理。ir，1 H nmr，13证实了所有产品的结构C nmr和ms。
• Synthesis and spectral properties of 2,3-dihydro-4-(<i>paramethylphenyl</i>)-7-[(<i>o, m-</i>, and<i>p</i>-substituted)phenoxy]-1<i>H</i>-1,5-benzodiazepine-2-thiones
  作者：Eduardo Corés Cortés、Mario Martínez Torres

  DOI：10.1002/jhet.5570340337

  日期：1997.5

  A series of twelve new 2,3-dihydro-4-(para-methylphenyl)-7-[(o-, m-, and p-substituted)phenoxy]-1H-1,5-benzodiazepine-2-thiones. which have potentially useful pharmacological properties, has been synthesized by condensing the 3,3-dimercapto-1-(p-methylphenyl)-2-propen-1-one with 3,4-diaminophenyl-R-phenyl ethers. The structure of all products was corroborated by ir; 1H-nmr; 13C-nmr and ms.

  一系列十二个新的2,3-二氢-4-（对甲基苯基）-7-[（邻，间和对取代的）苯氧基] -1 H -1,5-苯并二氮杂-2-硫酮。通过将3，3-二巯基-1-（对甲基苯基）-2-丙烯-1-酮与3，4-二氨基苯基-R-苯基醚缩合，合成了具有潜在有用药理性质的化合物。ir证实了所有产品的结构；1 H-核磁共振; 13 C-nmr和ms。
• Discovery of New Benzothiazole-Based Inhibitors of Breakpoint Cluster Region-Abelson Kinase Including the T315I Mutant
  作者：Seunghee Hong、Jinhee Kim、Sun-Mi Yun、Hyunseung Lee、Yoonsu Park、Soon-Sun Hong、Sungwoo Hong

  DOI：10.1021/jm301891t

  日期：2013.5.9

  The existence of drug resistance caused by mutations in the break-point cluster region-Abelson tyrosine kinase (Bcr-Abl) kinase domain remains a clinical challenge due to limited effective treatment options for chronic myeloid leukemia (CML). Herein we report a novel series of benzothiazole-based inhibitors that are effective against wild-type and T315I mutant Bcr-Abl kinases. The original hit compound, nocodazole, was extensively modified through a structure-based drug design strategy, especially by varying the groups at the C2 and C6 positions of the scaffold. In addition, the introduction of water-solubilizing groups at the terminal ethyl group resulted in enhanced physicochemical properties and potency in cellular inhibition. Several compounds inhibited the kinase activity of both wild-type Bcr-Abl and the T315I mutant with IC50 values in the picomolar range and exhibited good antiproliferative effects on Ba/F3 cell lines transformed with either wild-type or T315I mutant Bcr-Abl.